SecBot SecBot
8-K ·Filed Jul 24, 2026

INSP

Inspire Medical Systems, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001609550-26-000041
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine board appointment with no immediate trading implications. Monitor for any future strategic shifts if Carrel's med-tech expertise influences product or M&A direction.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$50.93
T+0 close · Jul 24, 2026 · via day close
Latest settled
+37.74%
T+60 · $70.15
Vs SPY
+34.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 27 $50.93entry
  2. T+1 · 4mo ago +2.04%α +1.80% · $51.97
  3. T+5 · 4mo ago −1.41%α −2.49% · $50.21
  4. T+20 · 3mo ago +20.70%α +17.40% · $61.47
  5. T+60 · 28d ago +37.74%α +34.03% · $70.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inspire Medical Systems appointed Michael H. Carrel, CEO of AtriCure (ATRC), to its Board of Directors effective July 20, 2026. This is a routine board addition with no financial impact or strategic change for the company.

Key Facts

  • Michael H. Carrel appointed to Inspire Medical Systems Board of Directors effective July 20, 2026
  • Carrel is President, CEO, and director of AtriCure, Inc. (NASDAQ: ATRC)
  • Carrel will serve as a Class III director until the 2027 Annual Meeting
  • Appointed to Organization and Compensation Committee and Quality, Product Supply and Technology Committee
  • Eligible for standard non-employee director compensation: $55,000 annual cash retainer, $7,500 per committee retainer, $300,000 initial RSU award vesting over 3 years, and $200,000 annual RSU award

Financial Impact

No material financial impact. Director compensation is standard and immaterial relative to company size.

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
36% bullish (25 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001609550-26-000041
Document: 0001609550-26-000041-index-headers.html0001609550-26-000041
Document: 0001609550-26-000041-index.html0001609550-26-000041
Document: 0001609550-26-000041.txt0001609550-26-000041

Track record

16 reports on INSP

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $59.52 Now $59.12 −0.67% settles Nov 17
  2. Nov 12, 20264d ago SC 13G/A Bearish 4/10 Entry $60.54 to $61.10 Now $59.12 +2.35% ▼ −0.93% −1.29% vs SPY
  3. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $62.31 to $62.11 Now $59.12 −5.12% ▼ −0.32% −1.64% vs SPY
  4. Nov 9, 20267d ago SC 13G/A Bearish 4/10 Entry $62.31 to $62.11 Now $59.12 +5.12% ▲ +0.32% +1.64% vs SPY
  5. Nov 2, 202614d ago 8-K Mixed 6/10 No price data
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $61.90 to $66.61 Now $59.12 −4.49% ▲ +7.61% +5.96% vs SPY
  7. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $68.10 to $67.21 Now $59.12 −13.19% ▼ −1.31% −0.83% vs SPY
  8. Oct 5, 20266w ago Press Release Neutral 1/10 Entry $68.20 Now $59.12 −13.31% No price data
  9. Jul 27, 202616w ago 3 Neutral 1/10 Entry $51.97 to $51.07 Now $59.12 +13.76% ▼ −1.73% −0.19% vs SPY
  10. Jul 24, 202616w ago 8-K Neutral 2/10 Viewing Entry $50.93 to $51.97 Now $59.12 +16.08% ▲ +2.04% +1.80% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 7h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 24, 2026